Top News
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Thanksgiving Weekend Brought New COVID-19 Concerns: The Omicron Variant
Livtencity Approved for Post-Transplant Cytomegalovirus Infection
RSNA: CT Imaging for Cancer Down During COVID-19 Peak in 2020
Incidence of Atrial Fibrillation Up After Breast Cancer Diagnosis
CLL Treatment May Increase Risk of Death From COVID-19
ONC201 Shows Clinical Efficacy in H3 K27M-Mutated Diffuse Midline Glioma
Excess Risk of CVD Low With Radiotherapy After Chemotherapy for Early-Stage Hodgkin Lymphoma
RSNA: Changes on Breast MRI Suggest Systemic Effects of LNG-IUD Use
Exposure to 17-OHPC in Utero Linked to Cancer Risk in Offspring
Indatuximab Ravtansine Has Encouraging Activity in Relapsed/Refractory Multiple Myeloma
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
COVID-19 Vaccine Boosters Appear Effective in Patients With Thoracic Cancer
Seroconversion was observed in 89% of patients who received a third vaccine dose. -
Daytime Infusions of Immunotherapy Tied to Better Survival in Advanced Melanoma
Receiving at least 20% of infusions after 4:30 pm was associated with shorter survival. -
Parents Report Challenging Relationships With Pediatric Oncology Clinicians
Asian parents were more likely to report challenging relationships. -
Men and Women Differ in Their Refusal of Breast Cancer Treatments
The odds of refusing hormone therapy, surgery, and radiation differed by sex. -
Digital Symptom Monitoring Can Improve Outcomes of Cancer Care
Patients experienced clinically meaningful benefits at various time points. -
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma. -
Treatment Sequence Impacts Survival in BRAF-Mutant Metastatic Melanoma
The 2-year overall survival rate was higher for patients who started treatment with nivolumab-ipilimumab than for those who started with dabrafenib-trametinib. -
Adding Ibrutinib to R-CHOP Doubles EFS in 2 Subgroups of Diffuse Large B-Cell Lymphoma
Younger patients with the MCD and N1 subtypes of DLBCL had 3-year event-free survival rates of 100% when they received ibrutinib plus R-CHOP. -
Racial/Ethnic Disparities in MRI Use May Affect Prostate Cancer Diagnosis
Asian, Black, and Hispanic patients were all less likely than White patients to undergo a prostate MRI.
More Features
Genetic Differences May Partly Explain Racial/Ethnic Disparities in Early-Onset Colorectal Cancer
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
Long-Term Benefit With Abemaciclib in High-Risk Early Breast Cancer
The benefit was maintained beyond the 2-year treatment period.
Docs Disagree With Update to NCCN Guidelines for Prostate Cancer
An update to active surveillance recommendations has some physicians concerned.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
- Loading...
Loading...
Loading... 
Loading...